MILESTONE SCIENTIFIC INC.MLSSEarnings & Financial Report
Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
MLSS Q3 2025 Key Financial Metrics
Revenue
$2.4M
Gross Profit
$1.6M
Operating Profit
$-1.1M
Net Profit
$-1.2M
Gross Margin
69.5%
Operating Margin
-48.1%
Net Margin
-48.9%
YoY Growth
-6.1%
EPS
$-0.01
Financial Flow
MILESTONE SCIENTIFIC INC. Q3 2025 Financial Summary
MILESTONE SCIENTIFIC INC. reported revenue of $2.4M for Q3 2025, with a net profit of $-1.2M (-48.9% margin). Cost of goods sold was $719.2K, operating expenses totaled $2.8M.
Key Financial Metrics
| Total Revenue | $2.4M |
|---|---|
| Net Profit | $-1.2M |
| Gross Margin | 69.5% |
| Operating Margin | -48.1% |
| Report Period | Q3 2025 |
MILESTONE SCIENTIFIC INC. Annual Revenue by Year
MILESTONE SCIENTIFIC INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $8.6M).
| Year | Annual Revenue |
|---|---|
| 2024 | $8.6M |
| 2023 | $9.8M |
| 2022 | $8.8M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.3M | $2.2M | $1.9M | $2.5M | $2.0M | $2.2M | $2.3M | $2.4M |
| YoY Growth | 0.9% | -13.4% | -36.3% | 22.1% | -10.9% | -0.7% | 25.3% | -6.1% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $11.4M | $11.4M | $12.0M | $11.2M | $9.8M | $9.1M | $8.1M | $8.5M |
| Liabilities | $3.4M | $3.9M | $4.1M | $4.0M | $4.0M | $4.6M | $4.7M | $5.9M |
| Equity | $8.0M | $7.5M | $8.0M | $7.2M | $5.8M | $4.5M | $3.3M | $2.5M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.2M | $-1.2M | $783655 | $-973914 | $-1.5M | $-1.0M | $-1.8M | $81775 |